Women Health Menstrual Care: CES 2026 An important and new technology to women’s health has emerged. Spark Biomedical has launched OhmBody has introduced an advanced wearable device by the name, which claims to reduce heavy menstrual bleeding without drugs, hormones or injections. According to the company, this device is based on nerve stimulation technology and provides a safer and more natural option than traditional treatment. OhmBody has been specially designed as a wellness product to provide relief to women who struggle with their periods every month.
During CES, Spark Biomedical representative Katherine Reil said that OhmBody is the result of the company’s old medical research. He said, “Our company is Spark Biomedical and we have worked on many health devices before.” The company already has an FDA-cleared device, which helps in opioid withdrawal. During the same research, it was understood that blood loss in the body can be controlled by activating nerve signals.
Initially this technology was thought of for diseases like hemophilia, but later the team realized that its biggest benefit could be in women’s menstrual health. Katherine Reil said, “OhmBody is a non-invasive and hormone-free device that aims to give women a more simple and manageable period experience.”
OhmBody stimulates the vagus and trigeminal nerves located around the ear. This process is called Transcutaneous Auricular Neurostimulation. The company claims that this stimulation balances the nervous system and has a direct effect on the blood flow of the body. Research also revealed that it activates platelets in the spleen, which can reduce bleeding.
Spark Biomedical has also shared the results of human trials to this device. Katherine Reil said, “Our research clearly showed that nerve stimulation reduces blood loss.” 16 women were included in this pilot study published in Frontiers journal. Women using OhmBody experienced an average of more than 50% reduction in blood loss and approximately 20% reduction in the length of periods. Also, improvement in pain, cramping and fatigue was also seen.
The company is going to start a new and larger clinical trial in February 2026, so that this technology can get stronger evidence as a medical product. At present, OhmBody is yet to get FDA clearance, but the company is working in this direction.
Katherine Reil said that till now there has been no open research and discussion on women’s health, especially periods. “The purpose of bringing OhmBody to a platform like CES is to further this discussion.”
Spark Biomedical is preparing to launch OhmBody on e-commerce and retail platforms through partnerships in the next three to five years. The company also aims to make it available to athletes and even Olympic training facilities.
